Medidata Unveils Bundled Solution For Oncology, Vaccine Research
KUALA LUMPUR, Nov 1 (Bernama) -- Medidata, a Dassault Systèmes brand and provider of clinical trial solutions to the life sciences industry, has introduced two new bundled offerings to meet the growing demands of oncology and vaccine research.
Medidata Oncology Solutions and Medidata Vaccine Solutions reinforce the Food and Drug Administration (FDA) guidance for patient-centred endpoints, adaptive trial designs, and trial diversity.
Both offerings combine a variety of Medidata technologies and learnings from thousands of previous trials to streamline study management for Phase II and Phase III studies in specified therapeutic areas, according to a statement.
By unifying key trial components such as real-time patient-reported outcomes and imaging management, these bundled solutions will aid sponsors by reducing trial complexity, accelerating decision-making, and improving assessments of treatment efficacy and safety.
"By making these new bundled capabilities readily available to customers, we can deliver a solution built on Medidata’s vast experience and expertise in these two important therapeutic areas.
“These bundles are designed to help customers navigate the complicated stages of these studies while advancing life-saving treatments,” said Medidata chief operating officer, Joseph Schmidt.
Medidata, with more than 25 years of oncology and vaccine experience and the largest global trial datasets, has conducted approximately 9,000 oncology studies and 750 trials in vaccines. In 2023, it was recorded that 93 per cent of oncology drug approvals went through Medidata.
The company was also on the frontlines of COVID-19, supporting hundreds of trials, including the development of one of the most effective messenger ribonucleic acid (mRNA) vaccines used to fight the virus.
Both solutions deliver a unified data ecosystem by integrating Medidata Rave EDC, Medidata eCOA, Medidata Rave Imaging, Medidata Clinical Data Studio, and Health Record Connect.
-- BERNAMA